证券日报网讯维力医疗（603309）11月24日在互动平台回答投资者提问时表示，公司根据上市公司相关 法规在定期报告披露公司股东人数，截至2025年9月30日，公司股东人数为18，890人。 ...

| 股票简称 | 股票代码 | 限售股类型 | 解禁股数 | | --- | --- | --- | --- | | 湖北能源 | 000883 | 股权激励限售流通 | 31.47万 | | 亚钾国际 | 000893 | 股权激励限售流通 | 240万 | | 南方航空 | 600029 | 增发A股原股东配售上市 | 8.04亿 | | 宁波韵升 | 600366 | 增发A股法人配售上市 | 3599.9万 | | 华兰生物 | 002007 | 股权激励限售流通 | 132.43万 | | 久其软件 | 002279 | 股权激励限售流通 | 244.78万 | | 吉峰科技 | 300022 | 股权激励限售流通 | 25万 | | 海默科技 | 300084 | 股权激励限售流通 | 270.9万 | | 金禾实业 | 002597 | 股权激励限售流通 | 54.64万 | | 维力医疗 | 603309 | 股权激励限售流通 | 3.3万 | | 艾德生物 | 300685 | 股权激励限售流通 | 153.63万 | | 海晨股份 | 300873 | 增发A股原股东配售上市 | 1726 ...

Core Viewpoint - The impact of the sixth round of national medical supplies procurement on the company is currently uncertain, as the official procurement plan has not yet been released [1] Group 1: Company Response - The company has established a dedicated department for procurement affairs management to study procurement policies and actively participate in each round of procurement [1] - The company aims to enhance the market coverage and share of its urology products in China through potential successful bids in this procurement round [1] - The company plans to implement cost reduction and efficiency improvement measures through production automation upgrades and technological advancements to enhance product profitability [1]

Core Insights - The report from Zhongyou Securities indicates that Weili Medical achieved a net profit attributable to shareholders of 192 million yuan in the first three quarters of 2025, representing a year-on-year growth of 14.94% [1] - In Q3, the net profit attributable to shareholders was 71 million yuan, reflecting a year-on-year increase of 16.31% [1] - The company's factory in Indonesia is nearing completion, with high-margin products increasingly contributing to revenue [1] Financial Performance - Net profit for the first three quarters of 2025 reached 192 million yuan, up 14.94% year-on-year [1] - Q3 net profit was 71 million yuan, marking a 16.31% year-on-year growth [1] Business Development - The Indonesian factory is currently in the construction and product certification phase, with expected shipments starting in the first quarter of 2026 [1] - The company is optimizing its overseas business product structure, with a continuous increase in the proportion of high-margin products [1] Future Outlook - The ongoing launch of new products is anticipated to further optimize the company's product and business structure [1] - The proportion of high-margin products is expected to continue rising, contributing to improved overall gross margins in overseas operations [1]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% relative to the benchmark index within the next six months [2][13]. Core Insights - The company achieved a revenue of 1.11 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 12.33%. The net profit attributable to the parent company was 192 million yuan, up 14.94% year-on-year [4]. - The company is set to begin shipments from its Indonesian factory by the end of Q1 2026, which is expected to significantly boost export orders, particularly for high-margin products [5]. - The proportion of high-margin products in the company's revenue has exceeded 20% and is expected to continue increasing due to enhanced overseas sales efforts and the introduction of new products [5]. Financial Performance - For 2025, the company forecasts revenues of 1.72 billion yuan, 2.02 billion yuan in 2026, and 2.34 billion yuan in 2027, with year-on-year growth rates of 14.09%, 17.36%, and 15.54% respectively [6]. - The net profit attributable to the parent company is projected to be 259 million yuan in 2025, 315 million yuan in 2026, and 374 million yuan in 2027, with corresponding growth rates of 18.25%, 21.38%, and 18.85% [6]. - The company's price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are estimated to be 15.87, 13.08, and 11.00 respectively, indicating a favorable valuation trend [6]. Business Strategy - The company has intensified its overseas expansion efforts, particularly in the urology product segment, which has shown significant growth in export revenues over the past two years [5]. - The Indonesian factory's initial capacity will primarily serve major clients in the U.S., focusing on the production of urinary catheters and suction connection tubes, with plans to expand into anesthesia products based on market demand [5].

Core Viewpoint - The company, Weili Medical (603309.SH), announced that its products, including disposable sterile catheters and ultrasound-guided nerve block anesthesia puncture needles, have been selected for the second batch of innovative drug and medical device product catalog in Guangzhou, which recognizes the technological advancement and innovation of the company's products [1] Summary by Category - **Product Recognition** - The inclusion of the products in the catalog is a recognition of the technological advancement and innovation of the company's offerings [1] - **Market Impact** - This recognition is expected to enhance the company's brand awareness and market competitiveness, positively influencing the sales of its innovative products [1] - **Short-term Financial Impact** - However, the short-term impact on the company's operating performance is expected to be minimal, and investors are advised to remain cautious regarding investment risks [1]

证券代码：603309 证券简称：维力医疗 公告编号：2025-062 公司上述创新产品入选《广州市创新药械产品目录》，是对公司产品技术先 进性、创新性的认可，有助于提高公司品牌知名度及市场竞争力，对公司创新产 品未来的销售具有积极影响。 公司将借本次入选为契机，继续加大创新药械的研发力度，增强自主创新能 力，积极推动广州市生物医药产业和医疗民生事业的创新发展。 四、风险提示 广州维力医疗器械股份有限公司 关于公司产品入选《广州市创新药械产品目录》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、基本情况 广州维力医疗器械股份有限公司（以下简称"公司"）于近日收到广州市工 业和信息化局通知，公司产品一次性使用无菌导尿管（国械注准20243141963）、 超声引导神经阻滞麻醉穿刺针（国械注准20243082067）2款产品入选广州市第二 批创新药械产品目录。 二、入选背景 广州市创新药械的征集和遴选，其核心是推动广州市生物医药这一战略性新 兴产业创新发展、打造全球产业高地，加快培育新动能，进一步促进创新药械产 品的市 ...

Core Insights - The National Medical Products Administration (NMPA) is enhancing the legal and standard system for medical devices, increasing support for R&D innovation, and improving review and approval efficiency to promote high-quality development in the medical device industry [1] Industry Developments - In the first eight months of this year, Beijing's exports of medical instruments and devices reached 5.83 billion yuan, a year-on-year increase of 21.5% [1] - The overseas market for medical devices is significantly larger than the domestic market, leading to high growth for many companies in international business [1] Innovation and Product Approvals - Under supportive policies, there has been a surge in innovative product approvals in the medical device sector [2] - David Medical's subsidiary received a registration certificate for a disposable endoscopic linear cutting stapler, enhancing the company's product line and core competitiveness [2] - The NMPA approved a new "Extended Depth of Focus Intraocular Lens" from Tianjin Century Kangtai Biomedical Engineering Co., which aims to improve vision correction post-cataract surgery [2] High-End Medical Imaging Equipment - Neusoft Medical's X-ray computed tomography device received approval, featuring higher spatial resolution and multiple energy imaging capabilities [3][4] - The NMPA is actively supporting the innovation of high-end medical devices, including photon-counting CT technology, which represents a significant advancement in imaging [4][5] Company Performance - Weili Medical reported a third-quarter revenue of 446 million yuan, a year-on-year increase of 16.09%, with a net profit of 70.57 million yuan, up 16.31% [6] - Xiangsheng Medical's revenue for the first three quarters was 343 million yuan, a decrease of 5.3%, while its net profit showed a slight decline [6] - Mindray Medical anticipates positive growth in its third-quarter revenue, with international business expected to accelerate [7] International Expansion - Companies are increasingly focusing on internationalization, with Mindray Medical planning to issue H-shares to enhance its global capital operations [8] - Weili Medical is constructing a factory in Indonesia, expected to start shipments by the end of Q1 2026, primarily supplying products to major clients in the U.S. [9] - The international business of medical device companies is projected to surpass domestic business in the future, with many companies transitioning from imitation to leading global innovation [10]

Group 1 - The core point of the news is that Weili Medical's stock price increased by 5.13% to 14.76 CNY per share, with a trading volume of 102 million CNY and a turnover rate of 2.44%, resulting in a total market capitalization of 4.308 billion CNY [1] - Weili Medical, established on April 30, 2004, and listed on March 2, 2015, specializes in the research, production, and sales of medical devices in various fields including anesthesia, urology, catheterization, nursing, respiratory care, and dialysis [1] - The revenue composition of Weili Medical is as follows: anesthesia 31.62%, catheterization 29.03%, urology 14.32%, nursing 11.45%, respiratory care 5.56%, dialysis 5.01%, and others 3.01% [1] Group 2 - From the perspective of Weili Medical's top ten circulating shareholders, a fund under China Merchants Fund, specifically the China Merchants Quantitative Selected Stock Initiation A (001917), entered the top ten circulating shareholders in the third quarter, holding 1.8866 million shares, which accounts for 0.65% of the circulating shares [2] - The estimated floating profit for this fund today is approximately 1.3584 million CNY [2] - The China Merchants Quantitative Selected Stock Initiation A (001917) was established on March 15, 2016, with a latest scale of 2.765 billion CNY, achieving a year-to-date return of 40.44% and a one-year return of 47.04% [2]

Core Viewpoint - The Social Security Fund's investment movements in the third quarter reveal a strategic shift, with notable changes in holdings across various stocks, indicating potential investment opportunities and sector performance trends [1][2][3][4] Group 1: Holdings Overview - The Social Security Fund appeared in the top ten shareholders of 33 stocks by the end of the third quarter, holding a total of 625 million shares valued at 13.07 billion yuan [1] - The fund maintained its position in 6 stocks, initiated positions in 7 stocks, increased holdings in 10 stocks, and reduced holdings in 10 stocks during the quarter [1] - The stock with the highest number of Social Security Fund shareholders is Sanhe Tree, with three funds listed among the top ten shareholders, holding a total of 15.02 million shares, accounting for 2.04% of the company's circulating shares [1] Group 2: Significant Holdings - The stocks with over 10 million shares held by the Social Security Fund include 17 stocks, with Poly Development having the largest holding of 124 million shares, which increased by 19.86 million shares in the third quarter [2] - China Jushi and CNOOC Development follow with holdings of 85.52 million shares and 55.16 million shares, respectively [2] - The highest holding percentage is in Baiya Shares, at 4.34% of circulating shares, with two funds increasing their holdings by over 3.18 million shares [2] Group 3: Market Performance - The newly acquired stocks by the Social Security Fund have seen an average increase of 0.28% since October, with Jinling Mining leading with a 10.36% increase [3] - Other notable performers include Koyuan Wisdom and Blue Science High-tech, with increases of 7.18% and 6.04%, respectively [3] - Among the new stocks, six reported year-on-year net profit growth, with Blue Science High-tech turning a profit with a net profit of 33.31 million yuan [3] Group 4: Performance of Increased Holdings - Among the stocks where the Social Security Fund increased its holdings, nine reported year-on-year net profit growth, with Xinqiang Lian turning a profit with a total revenue of 3.618 billion yuan, up 84.10% year-on-year [4] - The profit growth for Xinqiang Lian is attributed to the recovery in wind power demand and improved cost management [4] - Other companies with significant profit growth include Sanhe Tree, Stanley, Jiuzhou Pharmaceutical, Weili Medical, and Haida Group [4]